Recognition and management of severe asthma: A Canadian Thoracic Society position statement

References

• Government of Canada. Fast facts about asthma: Data compiled from the 2011 Survey on Living with Chronic Diseases in Canada. http://www.phac-aspc.gc.ca/cd-mc/crd-mrc/asthma_fs_asthme-eng.php. Accessed July 24, 2017.
   Google Scholar
• To T, Simatovic J, Zhu J, et al. Asthma deaths in a large provincial health system. A 10-year population-based study. Ann Am Thoracic Soc. 2014;11(8):1210–7.
   Google Scholar
• Why Asthma still Kills: The National Review of Asthma Deaths (NRAD) Confidential Enquiry Report. London: URCoP. www.rcplondon.ac.uk/sites/default/files/why-asthma-still-kills-full-report.pdf.
   Google Scholar
• Breathe: The Lung Association. Survey: Asthma not well-controlled for most Canadians. https://www.lung.ca/news/latest-news/survey-asthma-not-well-controlled-most-canadians Accessed April 14, 2017.
   Google Scholar
• Lougheed MD, Lemiere C, Ducharme FM, et al. Canadian Thoracic Society 2012 guideline update: diagnosis and management of asthma in preschoolers, children and adults. Can Respiratory J. 2012;19(2):127–64. doi:10.1155/2012/635624. PMID:22536582.
   PubMed Web of Science ®Google Scholar
• Ducharme FM, Dell SD, Radhakrishnan D, et al. Diagnosis and management of asthma in preschoolers: A Canadian thoracic society and Canadian paediatric society position paper. Paediatrics Child Health. 2015;20(7):353–71. doi:10.1093/pch/20.7.353.
   PubMed Web of Science ®Google Scholar
• Bahadori K, Doyle-Waters MM, Marra C, et al. Economic burden of asthma: a systematic review. BMC Pulmonary Med. 2009;9:24. doi:10.1186/1471-2466-9-24. PMID:19454036.
   PubMedGoogle Scholar
• Fajt ML, Wenzel SE. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. J Allergy Clin Immunology. 2015;135(2):299–310; quiz 1. doi:10.1016/j.jaci.2014.12.1871. PMID:25662302.
   PubMed Web of Science ®Google Scholar
• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respiratory J. 2014;43(2):343–73. doi:10.1183/09031936.00202013. PMID:24337046.
   PubMed Web of Science ®Google Scholar
• Aaron SD, Vandemheen KL, FitzGerald JM, et al. Reevaluation of diagnosis in adults with physician-diagnosed Asthma. Jama. 2017;317(3):269–79. doi:10.1001/jama.2016.19627. PMID:28114551.
   PubMed Web of Science ®Google Scholar
• Morton RW, Elphick HE, Rigby AS, et al. STAAR: a randomised controlled trial of electronic adherence monitoring with reminder alarms and feedback to improve clinical outcomes for children with asthma. Thorax. 2017;72(4):347–54. doi:10.1136/thoraxjnl-2015-208171. PMID:27815524.
   PubMed Web of Science ®Google Scholar
• Weinstein AG. Should patients with persistent severe asthma be monitored for medication adherence? Ann Allergy, Asthma Immunology : Official Publ Am College Allergy, Asthma, Immunology. 2005;94(2):251–7. doi:10.1016/S1081-1206(10)61304-X.
   Google Scholar
• Sanchis J, Gich I, Pedersen S. Systematic review of errors in inhaler use: Has patient technique improved over time?. Chest. 2016;150(2):394–406. doi:10.1016/j.chest.2016.03.041. PMID:27060726.
   PubMed Web of Science ®Google Scholar
• Gibeon D, Heaney LG, Brightling CE, et al. Dedicated severe asthma services improve health-care use and quality of life. Chest. 2015;148(4):870–6. doi:10.1378/chest.14-3056. PMID:25789861.
   PubMed Web of Science ®Google Scholar
• Schatz M, Rachelefsky G, Krishnan JA. Follow-up after acute asthma episodes: what improves future outcomes?. Proceedings of the American Thoracic Society. 2009;6(4):386–93. doi:10.1513/pats.P09ST6. PMID:19675349.
   PubMedGoogle Scholar
• McCallister JW, Parsons JP, Mastronarde JG. The relationship between gastroesophageal reflux and asthma: an update. Therapeutic Adv Respiratory Disease. 2011;5(2):143–50. doi:10.1177/1753465810384606. PMID:20926507.
   PubMedGoogle Scholar
• The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European network for understanding mechanisms of severe Asthma. Eur Respiratory J. 2003;22(3):470–7. PMID:14516137.
   PubMedGoogle Scholar
• Moore WC, Bleecker ER, Curran-Everett D, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol. 2007;119(2):405–13. doi:10.1016/j.jaci.2006.11.639. PMID:17291857.
   PubMed Web of Science ®Google Scholar
• Zazzali JL, Broder MS, Omachi TA, Chang E, Sun GH, Raimundo K. Risk of corticosteroid-related adverse events in asthma patients with high oral corticosteroid use. Allergy Asthma Proc. 2015;36(4):268–74. doi:10.2500/aap.2015.36.3863. PMID:26108084.
   PubMed Web of Science ®Google Scholar
• Lefebvre P, Duh MS, Lafeuille MH, et al. Acute and chronic systemic corticosteroid-related complications in patients with severe asthma. J. Allergy Clin Immunol. 2015;136(6):1488–95. doi:10.1016/j.jaci.2015.07.046. PMID:26414880.
   PubMed Web of Science ®Google Scholar
• Manson SC, Brown RE, Cerulli A, Vidaurre CF. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respiratory Med. 2009;103(7):975–94. doi:10.1016/j.rmed.2009.01.003. PMID:19372037.
   PubMed Web of Science ®Google Scholar
• Raissy HH, Kelly HW, Harkins M, Szefler SJ. Inhaled corticosteroids in lung diseases. Am J Respir Crit Care Med. 2013;187(8):798–803. doi:10.1164/rccm.201210-1853PP. PMID:23370915.
   PubMed Web of Science ®Google Scholar
• Kapadia CR, Nebesio TD, Myers SE, et al. Endocrine effects of inhaled Corticosteroids in children. JAMA Pediatrics. 2016;170(2):163–70. doi:10.1001/jamapediatrics.2015.3526. PMID:26720105.
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180(5):388–95. doi:10.1164/rccm.200903-0392OC. PMID:19483109.
   PubMed Web of Science ®Google Scholar
• Delvaux M, Henket M, Lau L, et al. Nebulised salbutamol administered during sputum induction improves bronchoprotection in patients with asthma. Thorax. 2004;59(2):111–5. doi:10.1136/thorax.2003.011130. PMID:14760148.
   PubMed Web of Science ®Google Scholar
• Gibson PG, Wlodarczyk JW, Hensley MJ, et al. Epidemiological association of airway inflammation with asthma symptoms and airway hyperresponsiveness in childhood. Am J Respir Crit Care Med. 1998;158(1):36–41. doi:10.1164/ajrccm.158.1.9705031. PMID:9655704.
   PubMed Web of Science ®Google Scholar
• ten Brinke A, de Lange C, Zwinderman AH, Rabe KF, Sterk PJ, Bel EH. Sputum induction in severe asthma by a standardized protocol: predictors of excessive bronchoconstriction. Am J Respir Crit Care Med. 2001;164(5):749–53. doi:10.1164/ajrccm.164.5.2009035. PMID:11549527.
   PubMed Web of Science ®Google Scholar
• Fleming L, Wilson N, Regamey N, Bush A. Use of sputum eosinophil counts to guide management in children with severe asthma. Thorax. 2012;67(3):193–8. doi:10.1136/thx.2010.156836. PMID:21825081.
   PubMed Web of Science ®Google Scholar
• Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology. 2006;11(1):54–61. doi:10.1111/j.1440-1843.2006.00784.x. PMID:16423202.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Brightling CE, Woltmann G, Wardlaw AJ. Non-eosinophilic corticosteroid unresponsive asthma. Lancet (London, England). 1999;353(9171):2213–4. doi:10.1016/S0140-6736(99)01813-9. PMID:10392993.
   PubMed Web of Science ®Google Scholar
• Nair P, Aziz-Ur-Rehman A, Radford K. Therapeutic implications of ‘neutrophilic asthma’. Current Opinion in Pulmonary Medicine. 2015;21(1):33–38.
   Google Scholar
• van Veen IH, Ten Brinke A, Gauw SA, Sterk PJ, Rabe KF, Bel EH. Consistency of sputum eosinophilia in difficult-to-treat asthma: a 5-year follow-up study. J Allergy Clin Immunology. 2009;124(3):615–7, 7.e1–2. doi:10.1016/j.jaci.2009.06.029.
   Google Scholar
• Ortega H, Chupp G, Bardin P, et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. Eur Respiratory J. 2014;44(1):239–41. doi:10.1183/09031936.00220413. PMID:24659543.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. New England J Med. 2014;371(13):1189–97. doi:10.1056/NEJMoa1403291. PMID:25199060.
   PubMed Web of Science ®Google Scholar
• Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Med. 2015;3(5):355–66. doi:10.1016/S2213-2600(15)00042-9. PMID:25736990.
   PubMed Web of Science ®Google Scholar
• Gibson PG, Yang IA, Upham JW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2017;390:659–68. doi:10.1016/S0140-6736(17)31281-3.
   Google Scholar
• Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602–15. doi:10.1164/rccm.9120-11ST. PMID:21885636.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Wenzel S, Rosen K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respiratory Critical Care Med. 2013;187(8):804–11. doi:.10.1164/rccm.201208-1414OC. PMID:23471469.
   PubMed Web of Science ®Google Scholar
• Teach SJ, Gill MA, Togias A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015;136(6):1476–85. doi:10.1016/j.jaci.2015.09.008. PMID:26518090.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet (London, England). 2012;380(9842):651–9. doi:10.1016/S0140-6736(12)60988-X. PMID:22901886.
   PubMed Web of Science ®Google Scholar
• Consult E-BM. Lab test: Eosinophil count. https://www.ebmconsult.com/articles/lab-test-eosinophil-count.
   Google Scholar
• Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax. 2013;68(4):322–9. doi:10.1136/thoraxjnl-2012-202698. PMID:23291349.
   PubMed Web of Science ®Google Scholar
• Busse W, Spector S, Rosen K, Wang Y, Alpan O. High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. J Allergy Clin Immunology. 2013;132(2):485–6.e11. doi:10.1016/j.jaci.2013.02.032. PMID:23591271.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England J Med. 2014;371(13):1198–207. doi:10.1056/NEJMoa1403290. PMID:25199059.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Med. 2016;4(7):549–56. doi:10.1016/S2213-2600(16)30031-5. PMID:27177493.
   PubMed Web of Science ®Google Scholar
• Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184(10):1125–32. doi:10.1164/rccm.201103-0396OC. PMID:21852542.
   PubMed Web of Science ®Google Scholar
• Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 study of Reslizumab in patients with poorly controlled Asthma: Effects across a broad range of Eosinophil counts. Chest. 2016;150(4):799–810. doi:10.1016/j.chest.2016.03.018. PMID:27018175.
   PubMed Web of Science ®Google Scholar
• Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled Asthma with elevated blood Eosinophil levels: A Randomized Phase 3 study. Chest. 2016;150:789–98. doi:10.1016/j.chest.2016.03.032. PMID:27056586.
   PubMedGoogle Scholar
• Nowak RM, Parker JM, Silverman RA, et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor alpha monoclonal antibody, after acute asthma. Am J Emergency Med. 2015;33(1):14–20. doi:10.1016/j.ajem.2014.09.036. PMID:25445859.
   PubMed Web of Science ®Google Scholar
• Castro M, Wenzel SE, Bleecker ER, et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respiratory Med. 2014;2(11):879–90. doi:10.1016/S2213-2600(14)70201-2. PMID:25306557.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet (London, England). 2016;388(10056):2115–27. doi:10.1016/S0140-6736(16)31324-1. PMID:27609408.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (London, England). 2016;388(10056):2128–41. doi:10.1016/S0140-6736(16)31322-8. PMID:27609406.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet (London, England). 2016;388(10056):2115–27. doi:10.1016/S0140-6736(16)31324-1. PMID:27609408.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med. 2000;161(5):1720–45. doi:10.1164/ajrccm.161.5.9903102. PMID:10806180.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respiratory Med. 2007;101(7):1483–92. doi:10.1016/j.rmed.2007.01.011. PMID:17339107.
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309–16. doi:10.1111/j.1398-9995.2004.00772.x. PMID:15679715.
   PubMed Web of Science ®Google Scholar
• Izuhara K, Ohta S, Ono J. Using Periostin as a biomarker in the treatment of Asthma. Allergy Asthma Immunol Res. 2016.;8(6):491–8. doi:10.4168/aair.2016.8.6.491. PMID:27582399.
   PubMed Web of Science ®Google Scholar
• Inoue Y, Izuhara K, Ohta S, Ono J, Shimojo N. No increase in the serum periostin level is detected in elementary school-age children with allergic diseases. Allergol Int. 2015;64(3):289–90. doi:10.1016/j.alit.2015.04.001. PMID:26117266.
   PubMedGoogle Scholar
• Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respiratory Critical Care Med. 2008;177(2):148–55. doi:10.1164/rccm.200707-1134OC. PMID:17947611.
   PubMed Web of Science ®Google Scholar
• (NICE) NIfHCE. Chronic obstructive pulmonary disease in over 16s: Diagnosis and maangement 2010. nice.org.uk/guidance/cg101.
   Google Scholar
• Kew KM, Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/.ICS for adults with asthma. Cochrane Database Syst Rev. 2016;(1):CD011721. PMID:26798035.
   PubMedGoogle Scholar
• Rodrigo GJ, Castro-Rodriguez JA. What is the role of tiotropium in asthma?: a systematic review with meta-analysis. Chest. 2015;147(2):388–96. doi:10.1378/chest.14-1698. PMID:25322075.
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Castro-Rodriguez JA. Tiotropium for the treatment of adolescents with moderate to severe symptomatic asthma: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2015;115(3):211–6. doi:10.1016/j.anai.2015.06.029. PMID:26231467.
   PubMed Web of Science ®Google Scholar
• Szefler SJ, Murphy K, Harper T, 3rd, et al. A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma. J Allergy Clin Immunol. 2017. In press. doi:10.1016/j.jaci.2017.01.014.
   Google Scholar
• Vogelberg C, Moroni-Zentgraf P, Leonaviciute-Klimantaviciene M, et al. A randomised dose-ranging study of tiotropium Respimat(R.) in children with symptomatic asthma despite inhaled corticosteroids. Respir Res. 2015;16:20. doi:10.1186/s12931-015-0175-9. PMID:25851298.
   PubMed Web of Science ®Google Scholar
• Huang J, Chen Y, Long Z, Zhou X, Shu J. Clinical efficacy of tiotropium in children with asthma. Pak J Med Sci. 2016;32(2):462–5. PMID:27182262.
   PubMed Web of Science ®Google Scholar
• Dahl R, Engel M, Dusser D, et al. Safety and tolerability of once-daily tiotropium Respimat((R)) as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: A pooled safety analysis. Respiratory Med. 2016;118:102–11. doi:10.1016/j.rmed.2016.07.001. PMID:27578478.
   PubMed Web of Science ®Google Scholar
• Lee SW, Kim HJ, Yoo KH, et al. Long-acting anticholinergic agents in patients with uncontrolled asthma: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2014;18(12):1421–30. doi:10.5588/ijtld.14.0275. PMID:25517806.
   PubMedGoogle Scholar
• Tian JW, Chen JW, Chen R, Chen X. Tiotropium versus placebo for inadequately controlled asthma: a meta-analysis. Respir Care. 2014;59(5):654–66. doi:10.4187/respcare.02703. PMID:24170916.
   PubMedGoogle Scholar
• Anderson DE, Kew KM, Boyter AC. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma. Cochrane Database Syst Rev. 2015;(8):CD011397. PMID:26301488Please provide missing [Volume number] for [Reference 69]..
   PubMedGoogle Scholar
• Kew KM, Evans DJ, Allison DE, Boyter AC. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma. Cochrane Database Syst Rev. 2015;(6):CD011438. PMID:26031392Please provide missing [Volume number] for [Reference 70]..
   PubMedGoogle Scholar
• Kew KM, Undela K, Kotortsi I, Ferrara G. Macrolides for chronic asthma. Cochrane Database Syst Rev. 2015;(9):CD002997. PMID:26371536Please provide missing [Volume number] for [Reference 71]..
   PubMedGoogle Scholar
• Kamada AK, Hill MR, Iklé DN, Brenner AM, Szefler SJ. Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. J Allergy Clin Immunol. 1993;91(4):873–82. doi:10.1016/0091-6749(93)90345-G. PMID:8473676.
   PubMedGoogle Scholar
• Strunk RC, Bacharier LB, Phillips BR, et al. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. J Allergy Clin Immunol. 2008;122(6):1138–44.e4. doi:10.1016/j.jaci.2008.09.028. PMID:18951618.
   PubMedGoogle Scholar
• Nelson HS, Hamilos DL, Corsello PR, Levesque NV, Buchmeier AD, Bucher BL. A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. Am Rev Respir Dis. 1993;147(2):398–404. doi:10.1164/ajrccm/147.2.398. PMID:8430965.
   PubMedGoogle Scholar
• Piacentini GL, Peroni DG, Bodini A, et al. Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. Allergy Asthma Proc. 2007;28(2):194–8. doi:10.2500/aap.2007.28.2958. PMID:17479604.
   PubMed Web of Science ®Google Scholar
• Mosholder AD, Mathew J, Alexander JJ, Smith H, Nambiar S. Cardiovascular risks with azithromycin and other antibacterial drugs. New England J Med. 2013;368(18):1665–8. doi:10.1056/NEJMp1302726. PMID:23635046.
   PubMed Web of Science ®Google Scholar
• Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. New England J Med. 2011;365(8):689–98. doi:10.1056/NEJMoa1104623. PMID:21864166.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, McNelley E, Kendall B, et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med. 2010;182(7):977–82. doi:10.1164/rccm.201003-0503OC. PMID:20508209.
   PubMed Web of Science ®Google Scholar
• Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunology (Baltimore, Md : 1950). 1993;151(5):2623–32. PMID:8360482.
   PubMed Web of Science ®Google Scholar
• Canada NP. Product Monograph: Xolair. 2017. https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94712.
   Google Scholar
• Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;(1): Cd003559. PMID:24414989Please provide missing [Volume number] for [Reference 81]..
   PubMedGoogle Scholar
• Holgate ST, Chuchalin AG, Hebert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy : J Br Soc Allergy Clin Immunol. 2004;34(4):632–8. doi:10.1111/j.1365-2222.2004.1916.x. PMID:15080818.
   PubMed Web of Science ®Google Scholar
• Bardelas J, Figliomeni M, Kianifard F, Meng X. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma. J Asthma. 2012;49(2):144–52. doi:10.3109/02770903.2011.648296. PMID:22277052.
   PubMed Web of Science ®Google Scholar
• Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol. 2003;91(2):154–9. doi:10.1016/S1081-1206(10)62170-9. PMID:12952109.
   PubMed Web of Science ®Google Scholar
• Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184–90. doi:10.1067/mai.2001.117880. PMID:11496232.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011;154(9):573–82. doi:10.7326/0003-4819-154-9-201105030-00002. PMID:21536936.
   PubMed Web of Science ®Google Scholar
• Niven R, Chung KF, Panahloo Z, Blogg M, Ayre G. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. Respir Med. 2008;102(10):1371–8. doi:10.1016/j.rmed.2008.06.002. PMID:18657960.
   PubMed Web of Science ®Google Scholar
• Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009;124(6):1210–6. doi:10.1016/j.jaci.2009.09.021. PMID:19910033.
   PubMed Web of Science ®Google Scholar
• Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. The Eur Respir J. 2001;18(2):254–61. doi:10.1183/09031936.01.00092101. PMID:11529281.
   PubMed Web of Science ®Google Scholar
• Milgrom H, Fick RB, Jr., Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. The New Engl J Med. 1999;341(26):1966–73. doi:10.1056/NEJM199912233412603. PMID:10607813.
   PubMed Web of Science ®Google Scholar
• Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004;59(7):709–17. doi:10.1111/j.1398-9995.2004.00550.x. PMID:15180757.
   PubMed Web of Science ®Google Scholar
• Rubin AS, Souza-Machado A, Andradre-Lima M, Ferreira F, Honda A, Matozo TM. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX). J Asthma. 2012;49(3):288–93. doi:10.3109/02770903.2012.660297. PMID:22356355.
   PubMed Web of Science ®Google Scholar
• Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy. 2004;59(7):701–8. doi:10.1111/j.1398-9995.2004.00533.x. PMID:15180756.
   PubMed Web of Science ®Google Scholar
• Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. The New Engl J Med. 2011;364(11):1005–15. doi:10.1056/NEJMoa1009705. PMID:21410369.
   PubMed Web of Science ®Google Scholar
• Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001;108(2):E36. doi:10.1542/peds.108.2.e36. PMID:11483846.
   PubMed Web of Science ®Google Scholar
• Karpel J, Massanari M, Geba GP, Kianifard F, Inhaber N, Zeldin RK. Effectiveness of omalizumab in reducing corticosteroid burden in patients with moderate to severe persistent allergic asthma. Ann Allergy Asthma Immunol. 2010;105(6):465–70. doi:10.1016/j.anai.2010.09.011. PMID:21130385.
   PubMedGoogle Scholar
• Kulus M, Hebert J, Garcia E, Fowler Taylor A, Fernandez Vidaurre C, Blogg M. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma. Curr Med Res Opin. 2010;26(6):1285–93. doi:10.1185/03007991003771338. PMID:20377320.
   PubMed Web of Science ®Google Scholar
• Busse WW, Morgan WJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. New England Journal of Medicine. 2011;364(11):1005–1015.
   PubMed Web of Science ®Google Scholar
• Garcia G, Magnan A, Chiron R, et al. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest. 2013;144(2):411–9. doi:10.1378/chest.12-1961. PMID:23579324.
   PubMed Web of Science ®Google Scholar
• de Llano LP, Vennera Mdel C, Alvarez FJ, et al. Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry. J Asthma. 2013;50(3):296–301. doi:10.3109/02770903.2012.757780. PMID:23350994.
   PubMed Web of Science ®Google Scholar
• Maselli DJ, Singh H, Diaz J, Peters JI. Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU/mL: a retrospective study. Ann Allergy Asthma Immunol. 2013;110(6):457–61. doi:10.1016/j.anai.2013.04.011. PMID:23706716.
   PubMed Web of Science ®Google Scholar
• Kornmann O, Watz H, Fuhr R, Krug N, Erpenbeck VJ, Kaiser G. Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table. Pulmonary Pharmacol Ther. 2014;28(2):149–53. doi:10.1016/j.pupt.2014.03.003.
   PubMed Web of Science ®Google Scholar
• Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;13. doi:10.1002/14651858.CD003559.pub4.
   Google Scholar
• Kim HL, Leigh R, Becker A. Omalizumab: Practical considerations regarding the risk of anaphylaxis. Allergy, Asthma, Clin Immunology: Official J Canadian Soc Allergy Clin Immunology. 2010;6(1):32. doi:10.1186/1710-1492-6-32. PMID:21129189.
   PubMedGoogle Scholar
• Cox L, Platts-Mills TA, Finegold I, Schwartz LB, Simons FE, Wallace DV. American academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol. 2007;120(6):1373–7. doi:10.1016/j.jaci.2007.09.032. PMID:17996286.
   PubMed Web of Science ®Google Scholar
• Long A, Rahmaoui A, Rothman KJ, et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol. 2014;134(3):560–7.e4. doi:10.1016/j.jaci.2014.02.007. PMID:24679845.
   PubMed Web of Science ®Google Scholar
• Busse W, Buhl R, Fernandez Vidaurre C, et al. Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol. 2012;129(4):983–9.e6. doi:10.1016/j.jaci.2012.01.033. PMID:22365654.
   PubMed Web of Science ®Google Scholar
• Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P. Safety and tolerability of omalizumab. Clin Exp Allergy : J British Soc Allergy Clin Immunology. 2009;39(6):788–97. doi:10.1111/j.1365-2222.2009.03214.x. PMID:19302249.
   PubMed Web of Science ®Google Scholar
• Mepolizumab (Nucala). Ottawa (ON): Product Monograph Nucala; 2016. https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93562.
   Google Scholar
• Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. The New Engl J Med. 2009;360(10):973–84. doi:10.1056/NEJMoa0808991. PMID:19264686.
   PubMed Web of Science ®Google Scholar
• Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007;176(11):1062–71. doi:10.1164/rccm.200701.-085OC. PMID:17872493.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. The New Engl J Med. 2014;371(13):1189–97. doi:10.1056/NEJMoa1403291. PMID:25199060.
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Singapuri A, et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. J Allergy Clin Immunol. 2014;133(3):921–3. doi:10.1016/j.jaci.2013.11.026. PMID:24418480.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang S, Li DW, Jiang SJ. Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials. PLoS One. 2013;8(3):e59872. doi:10.1371/journal.pone.0059872. PMID:23544105.
   PubMed Web of Science ®Google Scholar
• Powell C, Milan SJ, Dwan K, Bax L, Walters N. Mepolizumab versus placebo for asthma. Cochrane Database Syst Rev. 2015;(7):Cd010834. PMID:26214266.
   PubMedGoogle Scholar
• Li J, Wang F, Lin C, et al. The efficacy and safety of reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: A systematic review and meta-analysis. J Asthma. 2017;54(3):300–7. doi:10.1080/02770903.2016.1212371. PMID:27435534.
   PubMed Web of Science ®Google Scholar
• Nair P, Wenzel S, Rabe KF, et al. Oral Glucocorticoid-Sparing effect of Benralizumab in Severe Asthma. New Engl J Med. 2017;376(25):2448–58. doi:10.1056/NEJMoa1703501. PMID:28530840.
   PubMed Web of Science ®Google Scholar
• Cabon Y, Molinari N, Marin G, et al. Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials. Clin Exp Allergy: J Br Soc Allergy Clin Immunol. 2017;47(1):129–38. doi:10.1111/cea.12853. PMID:27859832.
   PubMed Web of Science ®Google Scholar
• Wang FP, Liu T, Lan Z, Li SY, Mao H. Efficacy and safety of Anti-Interleukin-5 therapy in patients with Asthma: A systematic review and meta-analysis. PLoS One. 2016;11(11):e0166833. doi:10.1371/journal.pone.0166833. PMID:27875559.
   PubMed Web of Science ®Google Scholar
• Miller JD, Cox G, Vincic L, Lombard CM, Loomas BE, Danek CJ. A prospective feasibility study of bronchial thermoplasty in the human airway. Chest. 2005;127(6):1999–2006. doi:10.1378/chest.127.6.1999. PMID:15947312.
   PubMed Web of Science ®Google Scholar
• Cox G, Miller JD, McWilliams A, Fitzgerald JM, Lam S. Bronchial thermoplasty for asthma. Am J Respir Crit Care Med. 2006;173(9):965–9. doi:10.1164/rccm.200507-1162OC. PMID:16456145.
   PubMed Web of Science ®Google Scholar
• Danek CJ, Lombard CM, Dungworth DL, et al. Reduction in airway hyperresponsiveness to methacholine by the application of RF energy in dogs. J Appl Physiol (Bethesda, Md : 1985). 2004;97(5):1946–53. doi:10.1152/japplphysiol.01282.2003. PMID:15258133.
   PubMed Web of Science ®Google Scholar
• Chakir J, Haj-Salem I, Gras D, et al. Effects of Bronchial Thermoplasty on airway smooth muscle and collagen deposition in Asthma. Ann Am Thoracic Soc. 2015;12.(11):1612–8. PMID:26325484.
   PubMed Web of Science ®Google Scholar
• Denner DR, Doeing DC, Hogarth DK, Dugan K, Naureckas ET, White SR. Airway Inflammation after Bronchial Thermoplasty for Severe Asthma. Ann Am Thoracic Soc. 2015;12(9):1302–9. doi:10.1513/AnnalsATS.201502-082OC. PMID:26230374.
   PubMedGoogle Scholar
• Pretolani M, Dombret MC, Thabut G, et al. Reduction of airway smooth muscle mass by bronchial thermoplasty in patients with severe asthma. Am J Respir Crit Care Med. 2014;190(12):1452–4. doi:10.1164/rccm.201407-1374LE. PMID:25496106.
   PubMed Web of Science ®Google Scholar
• Pretolani M, Bergqvist A, Thabut G, et al. Effectiveness of bronchial thermoplasty in patients with severe refractory asthma: Clinical and histopathologic correlations. J Allergy Clin Immunol. 2017;139(4):1176–85. doi:10.1016/j.jaci.2016.08.009. PMID:27609656.
   PubMed Web of Science ®Google Scholar
• Cox G, Thomson NC, Rubin AS, et al. Asthma control during the year after bronchial thermoplasty. New England J Med. 2007;356(13):1327–37. doi:10.1056/NEJMoa064707. PMID:17392302.
   PubMed Web of Science ®Google Scholar
• Castro M, Rubin AS, Laviolette M, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2010;181(2):116–24. doi:10.1164/rccm.200903-0354OC. PMID:19815809.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Cox G, Thomson NC, et al. Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. Am J Respir Crit Care Med. 2007;176(12):1185–91. doi:10.1164/rccm.200704-571OC. PMID:17901415.
   PubMed Web of Science ®Google Scholar
• Castro M, Rubin A, Laviolette M, Hanania NA, Armstrong B, Cox G. Persistence of effectiveness of bronchial thermoplasty in patients with severe asthma. Ann Allergy Asthma Immunol. 2011;107(1):65–70. doi:10.1016/j.anai.2011.03.005. PMID:21704887.
   PubMedGoogle Scholar
• Thomson NC, Rubin AS, Niven RM, et al. Long-term (5 year) safety of bronchial thermoplasty: Asthma Intervention Research (AIR) trial. BMC Pulmonary Med. 2011;11:8. doi:10.1186/1471-2466-11-8. PMID:21314924.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Laviolette M, Rubin AS, et al. Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol. 2013;132(6):1295–302. doi:10.1016/j.jaci.2013.08.009. PMID:23998657.
   PubMed Web of Science ®Google Scholar
• Doeing DC, Mahajan AK, White SR, Naureckas ET, Krishnan JA, Hogarth DK. Safety and feasibility of bronchial thermoplasty in asthma patients with very severe fixed airflow obstruction: a case series. J Asthma. 2013;50(2):215–8. doi:10.3109/02770903.2012.751997. PMID:23252954.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes. J Allergy Clin Immunol. 2015;136(3):531–45. doi:10.1016/j.jaci.2015.05.052. PMID:26343937.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention. GIfAGsfama. Updated 2015. http://ginasthma.org/wp-content/uploads/2016/01/GINA_Report_2015_Aug11-1.pdf.
   Google Scholar